115
Participants
Start Date
January 17, 2024
Primary Completion Date
December 30, 2025
Study Completion Date
December 30, 2027
GVM±R regimen
"Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician."
RECRUITING
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin
First Hospital of China Medical University
OTHER
Hebei Medical University Fourth Hospital
OTHER
Chengdu Shangjin Nanfu Hospital
UNKNOWN
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
OTHER
Xuanwu Hospital, Beijing
OTHER
The Affiliated Ganzhou Hospital of Nanchang University
OTHER
Beijing Tongren Hospital
OTHER
The First Affiliated Hospital of Dalian Medical University
OTHER
The First Hospital of Jilin University
OTHER
People's Hospital of Zhengzhou University
OTHER
The First Affiliated Hospital of Bengbu Medical University
OTHER
The Second Affiliated Hospital of Kunming Medical University
OTHER
The First Affiliated Hospital of Nanchang University
OTHER
The Second Affiliated Hospital of Harbin Medical University
OTHER
Shengjing Hospital
OTHER
Peking University Third Hospital
OTHER
First Affiliated Hospital of Harbin Medical University
OTHER
China-Japan Friendship Hospital
OTHER
Institute of Hematology & Blood Diseases Hospital, China
OTHER